Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I7HL
|
||||
| Former ID |
DNC007205
|
||||
| Drug Name |
2-phenylpropoxyadenosine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H23N5O5
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)CCCOC2=NC3=C(C(=N2)N)N=CN3C4C(C(C(O4)CO)O)<br />O
|
||||
| InChI |
1S/C19H23N5O5/c20-16-13-17(24(10-21-13)18-15(27)14(26)12(9-25)29-18)23-19(22-16)28-8-4-7-11-5-2-1-3-6-11/h1-3,5-6,10,12,14-15,18,25-27H,4,7-9H2,(H2,20,22,23)/t12-,14-,15-,18-/m1/s1
|
||||
| InChIKey |
UDWLAWJOABGYPL-SCFUHWHPSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [1] | |
| Adenosine A2a receptor | Target Info | Inhibitor | [1] | ||
| Adenosine A1 receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04022:cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation | |||||
| G alpha (s) signalling events | |||||
| Surfactant metabolismR-HSA-417973:Adenosine P1 receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCRs, OtherWP80:Nucleotide GPCRs | |||||
| Monoamine Transport | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2007 Apr 19;50(8):1810-27. Epub 2007 Mar 23.Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.